COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
Open Access
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 51, 102929
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
This publication has 8 references indexed in Scilit:
- COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic reviewMultiple Sclerosis and Related Disorders, 2021
- COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?Multiple Sclerosis and Related Disorders, 2021
- Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisAnnals of Neurology, 2021
- Normal antibody response after COVID-19 during treatment with cladribineMultiple Sclerosis and Related Disorders, 2020
- Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tabletsMultiple Sclerosis and Related Disorders, 2020
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisJAMA Neurology, 2020
- COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatmentMultiple Sclerosis Journal, 2020
- An Italian programme for COVID-19 infection in multiple sclerosisThe Lancet Neurology, 2020